Latest Breaking News On - Actinium pharmaceuticals inc - Page 10 : comparemela.com

Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual.

United statesSandesh sethAstellas pharmaActimaba national cancer instituteAmerican society of hematology annual meeting expositionOncology lg chem life sciencesActinium pharmaceuticals incExchange commissionHematology annual meetingMultiple high riskComplete remissionKarnofsky performance statusNational cancer instituteLife sciencesNews publishing

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

United statesHannah choeAstellas pharmaAvinash desaiAmerican society of hematology meeting expositionProfessor of medicine at ohio state universityPrnewswire actinium pharmaceuticals incOncology lg chem life sciencesActimaba national cancer instituteExchange commissionActinium pharmaceuticals incOverall survivalAnnual american societyHematology meetingComplete remissionAssistant professor

Actinium Pharma Reports Results From Phase 3 SIERRA Trial Of Iomab-B

Actinium Pharma Reports Results From Phase 3 SIERRA Trial Of Iomab-B
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStefan klotterAvinash desaiMore such health newsActinium pharmaceuticals incComplete remissionChief medical officerLassen sie

Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSandesh sethAstellas pharmaOncology lg chem life sciencesActimaba national cancer instituteActinium pharmaceuticals incPrnewswire actinium pharmaceuticals incAmerican society of hematology annual meeting expositionExchange commissionAnnual american societyHematology annual meetingMultiple high riskComplete remissionKarnofsky performance statusDose targeted radiationApamistamab prior

Actinium Pharma Reports Results From Phase 3 SIERRA Trial Of Iomab-B

Actinium Pharmaceuticals, Inc. reported results from the Phase 3 SIERRA trial of Iomab-B. The company said Iomab-B achieved the primary endpoint in the SIERRA trial of durable Complete Remission or dCR of at least 6 months with high statistical significance, with 22% of patients randomized to the Iomab-B arm achieving dCR and 0% of patients in the control arm achieving dCR, irrespective of TP53 mutational status.

Avinash desaiMore such health newsActinium pharmaceuticals incActinium pharmaceuticalsComplete remissionChief medical officer